TNYA
Tenaya Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$0.82+0.15%
Price as of Jul 20, 2026
TNYA financials
Tenaya Therapeutics, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $8.4M | $8.5M | $8.7M | $8.7M |
| Gross profit | -$8.4M | -$8.5M | -$8.7M | -$8.7M |
| Operating expenses | $84.9M | $107.5M | $122.5M | $116.9M |
| Operating income | -$93.3M | -$115.9M | -$131.2M | -$125.6M |
| Net income | -$90.6M | -$111.1M | -$124.1M | -$123.7M |
| EBITDA | -$82.2M | -$102.7M | -$115.4M | -$115.0M |
| Basic EPS | $-0.59 | $-1.31 | $-1.68 | $-2.76 |
| Diluted EPS | $-0.59 | $-1.31 | $-1.68 | $-2.76 |
| Balance sheet | ||||
| Cash & equivalents | $100.5M | $4.3M | $45.7M | $95.3M |
| Total assets | $146.9M | $119.9M | $170.5M | $278.9M |
| Total liabilities | $23.7M | $27.1M | $31.1M | $35.6M |
| Stockholders’ equity | $123.3M | $92.9M | $139.4M | $243.4M |
| Total debt | $10.8M | $13.6M | $12.4M | $15.1M |
| Net debt | -$89.7M | $9.3M | -$33.3M | -$80.2M |
| Cash flow | ||||
| Operating cash flow | -$68.3M | -$90.5M | -$102.1M | -$104.4M |
| Capital expenditure | -$618.0K | -$1.0M | -$1.2M | -$20.6M |
| Free cash flow | -$68.9M | -$91.5M | -$103.3M | -$125.1M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |